A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
about
Radiotherapy for the palliation of painful bone metastasesRadioisotopes for metastatic bone painRadioisotopes for metastatic bone painOverview of samarium sm 153 lexidronam in the treatment of painful metastatic bone diseaseTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerMinimally invasive local treatments for bone and pulmonary metastasesSamarium for osteoblastic bone metastases and osteosarcomaRadiotherapy for the palliation of painful bone metastases.Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.WITHDRAWN: Radioisotopes for metastatic bone pain.Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases.Prostate cancer pain management: EAU guidelines on pain management.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Bone Targeted Therapies for Bone Metastasis in Breast CancerRadionuclide Therapy of Bone Metastases.The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingStrengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Effectiveness of radioisotope therapy in bone metastases, based on personal experience.Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastasesBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancerThe influence of Sm-153 therapy on bone marrow functionThe role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons.Radium-223 dichloride for the treatment of metastatic prostate cancer.Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI.Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy.The Level of Europium-154 Contaminating Samarium-153-EDTMP Activates the Radiation Alarm System at the US Homeland Security Checkpoints.Treatment of bone pain secondary to metastases using samarium-153-EDTMP.Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.Evaluation of a method for activity estimation in Sm-153 EDTMP imaging.Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.153Sm: its use in multiple myeloma and report of a clinical experience
P2860
Q24202597-8B1670BC-EEAA-4E69-9DBE-E6B59E6561B9Q24235589-30B81DE3-84DE-4884-ADF7-31FA011A53B3Q24247773-CB77715B-F51D-43CC-8120-EA276409D00DQ24546181-6D564621-0ED9-4C87-8A28-429D15AEC272Q26752785-E977E7FB-F176-43F8-B038-16F0437AFC71Q26823733-27038551-CB7B-4622-A48E-64B959D62550Q26849767-38C166EF-8341-4DD5-84D4-0C273ED980D6Q28253337-19D97274-A27D-4ECE-A852-D02FF13D6519Q30868320-249EA503-C823-4FCE-819E-DDAC817CAAD3Q33387322-1444D7CC-FDDC-4BD6-B195-559E48E72A80Q33440341-1D619A72-1BDA-4D91-8814-7A6276E24CD7Q33909847-D64359CD-13EC-4EB9-92B3-9E34A63BAC38Q34154173-B601B6E0-3D10-483C-8952-51819336A0F8Q35057029-459EB9ED-D245-4D1A-B676-62D6E0395F39Q35750448-19427597-5EE9-4FDE-A464-D8ED2998522CQ36036136-DDB6949E-3AAA-4D55-9B03-AD0B8414804EQ36126003-7072B7A7-177B-4474-B2CD-CEBA3F648394Q36297804-729EBEE7-79B8-487D-BD4B-D36E1BF79BE5Q36840731-296F1793-E299-4915-B9D9-C2A80179EDBFQ36942561-E590F94C-576F-4A63-BAF1-B499ED7437DDQ37004657-4B7B9A5A-2D4F-4E61-BFF2-79650E3A368CQ37103630-8EFEF416-3208-478E-B839-96A2F46827FEQ37166534-3E57380A-A422-478E-96D5-1ACAC83687F6Q37187646-78A6A9EF-ACCF-4ACB-AED3-C4309F15C073Q37193613-7316B68E-8CA4-4EBE-8820-0A095AF8CBA8Q37727656-528E8CE4-DB1D-43FA-84A3-804AA9214207Q38001275-94F53A4E-8F3D-4AD8-A6AC-8C08DAED8790Q38004275-C75F120D-9C2B-4CC0-92D6-2595F57169C2Q39042390-875F8098-22BB-4C0D-BB99-27F1A182F1BCQ39135336-EB6F4552-7A32-4E43-96FF-180938FFA9B4Q41962075-559AA4C9-A78D-416D-9976-B866BA32CFC9Q42167680-A80C4BAE-C6A3-4ED4-8009-D39450657DE0Q42553058-775E357E-6538-4EB6-8104-B45FC385A6BCQ45159150-158CDE74-8B0F-4195-8914-A359F95C5AFCQ45227161-B458EB40-64C7-4BC7-9324-20A87DBBFD29Q45994851-605D1DE7-05C7-494D-9276-5C464901CFD9Q47684583-11024733-38B2-4597-841C-F262BFAE11D6Q49908522-63F81575-DA78-4068-B538-A3F47E0DFC00Q58449064-7834CDAF-7A50-4930-B1DA-8D460C447231
P2860
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
A dose-controlled study of 153 ...... with painful bone metastases.
@en
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate
@nl
type
label
A dose-controlled study of 153 ...... with painful bone metastases.
@en
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate
@nl
prefLabel
A dose-controlled study of 153 ...... with painful bone metastases.
@en
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate
@nl
P2093
P1476
A dose-controlled study of 153 ...... s with painful bone metastases
@en
P2093
I Fogelman
J F Chatal
P304
P356
10.1016/S0959-8049(97)00155-X
P577
1997-09-01T00:00:00Z